The Prevalence of Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma at One of the Largest Tertiary Care Centers in Sub-Saharan Africa.


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
01 08 2022
Historique:
accepted: 27 07 2021
pubmed: 7 12 2021
medline: 28 7 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

Limited data exist on the prevalence of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma in sub-Saharan Africa. To determine the prevalence of HPV-positive oropharyngeal squamous cell carcinoma at a large tertiary care center in South Africa. A total of 266 oropharyngeal squamous cell carcinomas diagnosed during an 11-year period (2007-2017) were selected for evaluation. Cases staining positive for p16 immunohistochemistry were evaluated for high-risk HPV using the BD Onclarity assay (BD Diagnostics, Sparks, Maryland). Of 266 oropharyngeal squamous cell carcinomas, 14% (n = 36) were positive for p16. Polymerase chain reaction for high-risk HPV performed on the p16-positive cases was negative in 23 cases and positive in 13 cases (13 of 266; 5%). p16 showed a positive predictive value of 36.1%. The HPV subtypes were HPV-16 (n = 10), HPV-18 (n = 1), HPV-52 (n = 1), and HPV-31 (n = 1). Human papillomavirus-positive cases occurred in 10 men and 3 women (mean age, 51 years) and arose from the tonsil (n = 10) or base of the tongue (n = 3). The HPV-positive cases were non-keratinizing (n = 10) or partially keratinizing (n = 1). Partially/nonkeratinizing cases revealed a modest improvement in p16 positive predictive value (11 of 21; 52.4%). The presence of high-risk HPV in 5% of cases suggests that high-risk HPV is a minor etiologic agent in oropharyngeal squamous cell carcinoma in this region. Given its suboptimal positive predictive value, p16 is not a reliable marker for high-risk HPV infection in this region. When p16 is positive, HPV-specific testing is necessary. The identification of less common high-risk HPV types, HPV-52 and HPV-31, may influence current local vaccination strategies.

Identifiants

pubmed: 34871360
pii: 474697
doi: 10.5858/arpa.2021-0021-OA
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p16 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1018-1023

Auteurs

Gloria Dapaah (G)

From the Department of Oral and Maxillofacial Pathology, National Health Laboratory Service, Tygerberg Academic Hospital, University of the Western Cape, Cape Town, South Africa (Dapaah, Hille, Opperman, Afrogheh).

Jos Hille (J)

From the Department of Oral and Maxillofacial Pathology, National Health Laboratory Service, Tygerberg Academic Hospital, University of the Western Cape, Cape Town, South Africa (Dapaah, Hille, Opperman, Afrogheh).

William C Faquin (WC)

From the Pathology Service, Massachusetts General Hospital, Harvard Medical School, Boston (Faquin).

Judith Whittaker (J)

From Lancet Laboratories, Cape Town, South Africa (Whittaker, Dittrich).

Corneli M Dittrich (CM)

From Lancet Laboratories, Cape Town, South Africa (Whittaker, Dittrich).

Abdul-Kader Ebrahim (AK)

From the Department of Ear, Nose and Throat (Ebrahim, Merven, Loock), Tygerberg Academic Hospital, University of Stellenbosch, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Johann W Schneider (JW)

From the Division of Anatomical Pathology, National Health Laboratory Service (Schneider, van Wyk), Tygerberg Academic Hospital, University of Stellenbosch, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Abraham C van Wyk (AC)

From the Division of Anatomical Pathology, National Health Laboratory Service (Schneider, van Wyk), Tygerberg Academic Hospital, University of Stellenbosch, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Johan Opperman (J)

From the Department of Oral and Maxillofacial Pathology, National Health Laboratory Service, Tygerberg Academic Hospital, University of the Western Cape, Cape Town, South Africa (Dapaah, Hille, Opperman, Afrogheh).

Marc Merven (M)

From the Department of Ear, Nose and Throat (Ebrahim, Merven, Loock), Tygerberg Academic Hospital, University of Stellenbosch, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Komeela Naidoo (K)

From the Division of Radiation Oncology, Department of Medical Imaging and Clinical Oncology (Naidoo), Tygerberg Academic Hospital, University of Stellenbosch, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

James W Loock (JW)

From the Department of Ear, Nose and Throat (Ebrahim, Merven, Loock), Tygerberg Academic Hospital, University of Stellenbosch, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Amir H Afrogheh (AH)

From the Department of Oral and Maxillofacial Pathology, National Health Laboratory Service, Tygerberg Academic Hospital, University of the Western Cape, Cape Town, South Africa (Dapaah, Hille, Opperman, Afrogheh).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH